People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

15 Nov 2019
Change (% chg)

$0.04 (+1.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bauersmith, James 

Mr. James Edward Bauersmith is Senior Vice President, Corporate Development of the Company. Jamie leads the Corporate Development, Portfolio and Procurement team’s activities focused on identifying opportunities for Amneal, both internal and external, to expand its capabilities, product portfolio and pipeline in Generics, Specialty and biosimilars. Prior to joining Amneal, Jamie served as SVP, Head of Portfolio and Strategic Marketing for Fresenius Kabi where he managed a team responsible for new product development, on-market products, new technology platforms, regulatory approval, procurement, launch management, and business development. Prior to joining Fresenius Kabi, Jamie served as a Senior Counsel for Teva Pharmaceuticals, where he oversaw several of the company’s Hatch-Waxman cases (branded and generic), including Copaxone. He also worked as a patent attorney in the New York office of Frommer Lawrence & Haug on Hatch-Waxman patent litigations) and handled a variety of patent prosecution, trademark, antitrust and unfair competition law topics. He has significant experience with the FTC, FDA, and go-to-market considerations across injectables and retail product lines. Jamie received his B.S. from the University of Notre Dame, his JD from Pennsylvania State University Dickinson School of law, where he graduated with Honors, and an M.S. of Bioscience and Biotechnology from Drexel University focused on molecular cell biology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Paul Bisaro


Chintu Patel


Chirag Patel


Robert Stewart


Kanwal Pandita


Todd Branning

As Of  31 Dec 2018